Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour

Figures & data

Table I. Tumour characteristics and surgical management.

Patient	Sex	Primary site	Surgery for primary (yes/no)	Surgery for recurrent/metastatic disease prior to systemic tx (x times)	Time to first line palliative tx (months)	Mets or local recurrence at the time of chemotherapy	Sites of mets
1	F	pleura	yes	2	63	mets	lungs
2	M	abdomen	yes	no	44	mets	lungs
3	M	paraspinal area	yes	2	91	mets	thoracic spine (T6)
4	M	pelvis	yes	2	36	mets	abdomen
5	M	pelvis	yes	1	76	local recurrence and mets	lungs
6	M	pelvis	yes	no	10	mets	lungs
7	F	pleura	yes	no	44	local recurrence and mets	lungs
8	M	abdomen	yes	no	17	mets	liver
9	F	abdomen	yes	no	12	local recurrence	NA
10	F	lower limb	yes	no	8	mets	lungs, liver, bone
11	F	breast	no	no	15	mets	liver, adrenal abdomen, subcut
12	F	pleura	yes	no	20	local recurrence and mets	peritoneal, retroperitoneal, lungs, L chest wall
13	F	pleura	yes	1	12	mets	lungs
14	M	pleura	yes	no	28	mets	lung, liver
15	M	abdomen	yes	no	32	mets	abdomen, pelvis
16	M	abdomen	yes	no	28	mets	liver, abdomen
17	F	lower limb	yes	no	38	mets	pelvis, bone, lung
18	F	pelvis	no	no	19	mets	lung, liver, bone
19	M	abdomen	no	no	3	mets	peritoneal, omental,
20	M	abdomen	yes	no	11	mets	gluteal muscle, pancreas, ribs
21	M	abdomen	yes	2	228	mets	liver
22	M	pleura	yes	no	156	mets	lung, mediastinal Lnpathy
23	M	lower limb	no	no	4	mets	lung, bone
24	M	lung	yes	no	13	mets	lung, Lnpathy

Table II. First line regimens for 24 patients and their response.

Patient	8.522 pt	Best response	Response at the end of tx	Tx duration (weeks)	Time to PD (weeks)
1	CHR2797	SD	SD	8	12
2	Trabectedin	SD	PD	6	8
3	Ifos/Epi	SD	PD	12	32
4	Ifos/Dox	SD	PD	12	12
5	Ifos/Dox/DTIC	SD	SD	18	12
6	Doxorubicin	SD	PD	18	16
7	Doxorubicin	SD	PD	12	12
8	Doxorubicin	PR	PR	18	44
9	Doxorubicin	PD	PD	6	8
10	Doxorubicin	SD	PD	8	8
11	Doxorubicin	SD	SD	18	48
12	Doxorubicin	SD	SD	15	36
13	Doxorubicin	SD	SD	18	32
14	Axitinib	SD	SD	10 +	10 +
15	Doxorubicin	SD	PD	12	12
16	Temozolomide/Bev	SD	PD	8	12
17	Temozolomide/Bev	SD	SD	24	48
18	Doxorubicin	SD	SD	18	36
19	Doxorubicin	SD	SD	18	24
20	Axitinib	SD	SD	3 +	3 +
21	Doxorubicin	PD	PD	6	8
22	Doxorubicin	SD	SD	18	36
23	Axitinib	SD	SD	6 +	6 +
24	Doxorubicin	PD	PD	3	3

Bev, Bevacizumab; DTIC, Dacarbazine; Dox, Doxorubicin; Epi, Epirubicin; Ifos, Ifosfamide; PD, progressive disease; SD, stable disease; Tx, treatment; (+), continues on treatment.

Figure 1. Overall survival from start of first-line chemotherapy for 17 patients